Produção Nacional
Revisado por pares
Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study
2023; Elsevier BV; Linguagem: Inglês
10.1016/j.pulmoe.2023.07.004
ISSN2531-0437
AutoresBernardo Sousa‐Pinto, Renaud Louis, Josep M. Antó, Rita Amaral, Ana Sá‐Sousa, Heather J. Zar, Luisa Brussino, Giorgio Walter Canonica, Cláudia Chaves Loureiro, Álvaro A. Cruz, Bilun Gemicioğlu, Tari Haahtela, Maciej Kupczyk, Violeta Kvedarienė, Désirée Larenas‐Linnemann, Yoshitaka Okamoto, Markus Ollert, Oliver Pfaar, N. Pham‐Thi, Francesca Puggioni, Frederico S. Regateiro, Jan Romantowski, J. Sastre, Nicola Scichilone, Luís Taborda‐Barata, Maria Teresa Ventura, Ioana Agache, Anna Bedbrook, Sven Becker, Karl‐Christian Bergmann, Sinthia Bosnic‐Anticevich, Matteo Bonini, L.‐P. Boulet, Guy Brusselle, Roland Buhl, Lorenzo Cecchi, D. Charpin, F. de Blay, Stefano Del Giacco, Juan Carlos Ivancevich, Marek Jutel, Ludger Klimek, Helga Kraxner, Piotr Kuna, D. Laune, Mika J. Mäkelä, Mário Morais‐Almeida, Rachel Nadif, Marek Niedoszytko, Nikolaos G. Papadopoulos, Alberto Papi, Vincenzo Patella, Benoît Pétré, Daniela Rivero‐Yeverino, Carlos Robalo Cordeiro, Nicolás Roche, Philip W. Rouadi, Bolesław Samoliński, Marine Savouré, Mohamed H. Shamji, Aziz Sheikh, Charlotte Suppli Ulrik, Omar S. Usmani, Arūnas Valiulis, Arzu Yorgancıoğlu, Torsten Zuberbier, João Fonseca, Elı́sio Costa, Jean Bousquet,
Tópico(s)Allergic Rhinitis and Sensitization
ResumoAdherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA.We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day.In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001).In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.
Referência(s)